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with the initial dosing regimen was measured using the Medica-
tion Possession Ratio (MPR). To identify determinants of non-
compliance, non-compliant patients (MPR < 50%) were
compared to compliant patients (MPR °Y´ 80%). The effect of
dosing regimen, patient age, prescriber, co-medication and frac-
tures on non-compliance was investigated. For independent
factors increasing non-compliance the Population Attributable
Risk percentage (PAR%) was determined. RESULTS: The study
cohort included 4699 (53%) compliant and 3089 (35%) non-
compliant users of daily or weekly bisphosphonates. A total of
1034 (12%) patients had a MPR °Y´ 50% and <80% over the
ﬁrst year. Use of daily bisphosphonates, number of different co-
medications used, and use of gastrointestinal medication during
the ﬁrst year were associated with an increased risk of non-
compliance (OR 3.1, 95% CI 2.7–3.5; OR 1.8, 95% CI 1.3–2.3
for >10 different co-medications; and OR 1.2; 95% CI 1.1–1.4,
respectively). Corresponding PAR% were 42%, 14% and 6%,
respectively. In contrast, higher age, ﬁrst prescription from a 
specialist, use of NSAIDs and hospitalization for osteoporosis 
or osteoporotic fracture in the year preceding bisphosphonate
therapy independently decreased the risk of non-compliance.
CONCLUSIONS: These results indicate that daily, rather than a
weekly, dosing regimen is the most important independent 
determinant of non-compliance with bisphosphonates. However,
compliance for both regimens can be considered to be subopti-
mal and leaves room for improvement.
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OBJECTIVES: Thrombocytopenia is a serious complication that
may occur in patients receiving venous thromboembolism pro-
phylaxis for a variety of reasons, including drug-induced throm-
bocytopenia. This analysis was conducted to assess if differences
exist in the coded rates of thrombocytopenia in patients receiv-
ing fondaparinux, dalteparin, enoxaparin, or unfractionated
heparin (UFH). METHODS: This was a retrospective analysis of
inpatient data from >500 hospitals in the United States. Patients
hospitalized for hip or knee replacement or hip fracture surgery
between 1/2003 and 3/2005 were eligible for study inclusion.
Patients receiving fondaparinux, dalteparin, enoxaparin or UFH
<2 days after surgery were included. A control group of ortho-
pedic surgery patients that did not receive any of the anticoagu-
lants of interest was also identiﬁed. Patients <18yrs of age or
those receiving >1 anticoagulant of interest during their hospi-
talization were excluded. The occurrence of thrombocytopenia
was determined by the presence an ICD-9 code for thrombocy-
topenia unspeciﬁed (287.5) and/or secondary thrombocytopenia
due to circulating anticoagulants (287.4 with E934.2). Logistic
regression models were used to assess differences in thrombocy-
topenia rates; controlling for age, gender, severity of illness
(Charlson), length of stay, number of hospitalizations prior to
index visit, type of orthopedic surgery, and cancer diagnosis.
RESULTS: A total of 250,600 patients were included in the
analysis: fondaparinux = 11,633; dalteparin = 14,713; enoxa-
parin = 92,776; UFH = 18,904; control = 112,574. The unad-
justed rates of thrombocytopenia in each cohort were:
fondaparinux = 0.8%, dalteparin = 1.2%, enoxaparin = 1.4%,
UFH = 1.3%, control = 0.9%. After controlling for baseline
covariates, patients on fondaparinux were least likely to experi-
ence thrombocytopenia. The odds of thrombocytopenia for each
anticoagulant when compared to control were: fondaparinux
OR = 0.98, p = 0.83; dalteparin OR = 1.2, p = 0.02; enoxaparin
OR = 1.3, p < 0.0001; UFH OR = 1.2, p = 0.03. CONCLU-
SIONS: Although the relative rates of drug-induced thrombocy-
topenia cannot be deﬁned with certainty (coding limitations), the
risk of thrombocytopenia in fondaparinux-treated patients was
similar to control, while patients receiving heparins experienced
an increased risk.
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OBJECTIVE: To estimate the economic and health impact of
managing bradycardia by implanting a dual chamber pacemaker
equipped with a new algorithm (Adapta) to avoid unnecessary
right ventricular pacing compared to a standard dual chamber
pacemaker (DDDR) in Sweden. The algorithm allows the pace-
maker to provide atrial pacing, and switch to dual-chamber
pacing whenever needed. This may lower the risk of developing
heart failure or atrial ﬁbrillation. METHODS: A life-time dis-
crete event simulation was developed to follow a patient’s course
after implantation with a pacemaker. Pairs of identical patients
are created; one receives Adapta, the other DDDR. Each patient
may develop post-operative complications, heart failure, atrial
ﬁbrillation (which may become chronic and require anticoagu-
lants) or have a stroke. Risks for these events depend on cumu-
lative time exposed to ventricular pacing and patient’s
characteristics based on published data from the MOST trial.
Life expectancy is assumed to be identical for both cohorts of
patients. Distributions of ventricular pacing are based on data
collected during trials of these devices. Direct medical costs
drawn from published NORD-DRG payments and physician,
laboratory and medication tariffs are reported in 2005 SEK and
discounted at 3%. RESULTS: Average life expectancy post-
implantation was found to be 11.8 years for both groups. Dis-
counted costs over life-time were about SEK200,000 (€21,220)
per patient. Despite the higher initial cost of Adapta, mean addi-
tional cost was only SEK13,430 (€1425) per patient. Adapta 
is predicted to increase QALY by a mean 0.23 years, yielding 
an incremental cost-effectiveness ratio of SEK45,961/QALY
(€4878/QALY). Sensitivity analyses showed results were consis-
tent over a wide range of values. CONCLUSION: Based on these
discrete event simulations estimates, Adapta is predicted to
provide additional health beneﬁts for an attractive value for
patients with sinoatrial-node disease or intermittent atrioven-
tricular block.
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OBJECTIVE: Lymphatic Filariasis (LF), an eradicable infectious
disease endemic in developing countries, is associated with sig-
niﬁcant morbidity. LF is the second leading cause of permanent
and long-term disability worldwide. Total global prevalence of
